Citalopram Hydrobromide (CIPRAMIL Citalopram hydrobromide 20mg tablet blister pack)
What to know about Citalopram Hydrobromide — also sold as CIPRAMIL Citalopram hydrobromide 20mg tablet blister pack, CELAPRAM citalopram 20mg (as hydrobromide) tablet blister pack, CELAPRAM citalopram 20mg (as hydrobromide) tablet bottle: uses, side effects, interactions, and safety considerations for people taking it or caring for someone who is.
Citalopram Hydrobromide (brand names: CIPRAMIL Citalopram hydrobromide 20mg tablet blister pack, CELAPRAM citalopram 20mg (as hydrobromide) tablet blister pack, CELAPRAM citalopram 20mg (as hydrobromide) tablet bottle) is classified as Low risk (2 risk points) by AllMeds. It is a S4 medication under the TGA in Australia. FDA approved in the United States. SSRI antidepressant with QTc prolongation risk and potential for cognitive side effects.
Key Takeaways
- TGA Schedule: S4 in Australia
- Risk level: Low (2 points)
- Serotonergic: Risk of serotonin syndrome when combined with other serotonergic drugs
Scheduling and Classification
| Jurisdiction | Classification | Status |
|---|---|---|
| Australia (TGA) | S4 | Not PBS listed |
| United States (FDA) | Rx only | FDA approved |
Risk Profile
SSRI antidepressant with QTc prolongation risk and potential for cognitive side effects.
How Citalopram Hydrobromide is regulated
Citalopram Hydrobromide is overseen by medicines regulators in each country. The rules below explain how it's scheduled, what oversight applies, and what to discuss with your doctor or pharmacist before starting, changing, or stopping this medication.
Australia TGA / PBS / State Schemes
Classified as S4 under the Therapeutic Goods Administration (TGA).
United Kingdom NICE / MHRA / FPM
NICE guidelines recommend certain antidepressants (amitriptyline, duloxetine) for chronic pain management. For personal injury claims, antidepressant prescribing should be assessed for injury relatedness.
United States FDA / CDC / State WC
FDA approved for use in the United States.
FDA Boxed Warning: WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1) ] . Citalopram is not approved for use in pediatric patients [see Use in Specific Populations (8.4) ]. WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Increased risk of suicidal thoughts and behavior in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 ) . Citalopram is not approved for use in pediatric patients ( 8.4 ).
Check this medication against your full medication list
Run a full risk assessment including Citalopram Hydrobromide interactions and compliance checks.
Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile in minutes. Free for individuals; team plans for case managers, insurers, and schemes.
Important: This page is general health information, not personal medical advice. If you have questions about your medication — including starting it, stopping it, changing the dose, or combining it with something else — speak with your doctor or pharmacist. For an emergency or suspected overdose, call your local emergency number or poison information service immediately. Information is drawn from regulator and clinical guideline sources (TGA, FDA, MHRA, NICE, PBS, CDC); see our methodology for details.